Knowledge Library

PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

Resource Type: Latest Science Poster
Resource Topic: CAR-T Oncology & Immuno-oncology

VIEW

Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses

While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >

Resource Type: Latest Science Poster
Resource Topic: Oncology & Immuno-oncology Oncolytic Viruses

VIEW

Validation of GVHD in mouse model for preclinical efficacy screen

AACR Annual meeting 2021 Na Xu, Ya Zhang, Rou Xie, Lijun Jia, Yingying Cai, Qing Lin Oncology and Immunology Unit, WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China Background Bone marrow transplantation has been successfully and widely used to treat diseases such as leukemia and lymphomas. However, the complication Graft …Read More >

Resource Type: Poster
Resource Topic: Tumor Models

VIEW

CRISPR library screens identify frequent cancer mutations regulating PD-1 blockade response

AACR Annual meeting 2021 Wenrong Zhou1,* , Min Long2,3* , Tianyu Song3,* , Qiangqiang Fan1 , Zhengang Peng1 , Yong Cang3 , Qunsheng Ji1  1 Oncology and Immunology Unit, Research Service Division, WuXi AppTec (Shanghai) Co., Ltd., China; 2 Life Sciences Institute, Zhejiang University, Hangzhou, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, …Read More >

Resource Type: Poster
Resource Topic: CRISPR/Cas9 Oncology & Immuno-oncology

VIEW

Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer

 AACR Annual meeting 2021   Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec, Shanghai, China; 2 WuXi AppTec, Jiangsu, China Corresponding Author: Qunsheng Ji. Email: ji_qunsheng@wuxiapptec.com   Background  Many cancer types are driven by specific gene aberrances, like gene fusions, mutations and copy number changes. It has led to …Read More >

Resource Type: Poster
Resource Topic: Oncology & Immuno-oncology

VIEW

Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics

AACR Annual meeting 2021  Ting Ni, Zhixiang Zhang, Xuzhen Tang, Hui Qi, Jingying Zhang, Ke Mao, Wenting Shi, Qingyang Gu, Qunsheng Ji WuXi AppTec, Suzhou, China  Abstract Recent advances in cancer biology and diagnosis are providing more targeted approaches to treat cancers. Therapy targeting the specific oncogenic driver could inhibit tumor progression and helps to …Read More >

Resource Type: Poster
Resource Topic: Oncology & Immuno-oncology

VIEW

Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors

Resource Type: Poster
Resource Topic: Cancer Research Oncology & Immuno-oncology

VIEW